Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKβ

Blood

Volumn 107, Issue 11, 2006, Pages 4266-4273

  Nagashima, Kumiko ^a,b   Sasseville, Vito G ^a   Wen, Danyi ^a   Bielecki, Andrew ^a   Yang, Hua ^a   Simpson, Chris ^a   Grant, Ethan ^a   Hepperle, Michael ^a   Harriman, Gerry ^a   Jaffee, Bruce ^a   Ocain, Tim ^a   Xu, Yajun ^a   Fraser, Christopher C ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ML 120B; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; GRANULOCYTE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPLEEN; THYMOCYTE;

EID: 33744502595     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3852     Document Type: Article

References (56)

1. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107:135-142.
2. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Disc. 2004;3:17-26.
3. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-260.
4. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell. 2002;109(suppl):S81-S96.
5. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med.1997;336:1066-1071.
6. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science. 1999;284:321-325.
7. Li ZW, Chu W, Hu Y, et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med. 1999;189:1839-1845.
8. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol. 2000;18:621-663.
9. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol. 2002;3:221-227.
10. Hu MC, Lee DF, Xia W, et al. IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 2004;117:225-237.
11. Kops GJ, Medema RH, Glassford J, et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol. 2002;22:2025-2036.
12. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like forkhead transcription factors mediate cell cycle regulation by Ras and PKB through p27kip1. Nature. 2000;404:782-787.
13. Alvarez B, Martinez AC, Burgering BM, Carrera AC. Forkhead transcription factors contribute to the execution of the mitotic programme in mammals. Nature. 2001;413:744-747.
14. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and exhibiting a Forkhead transcription factor. Cell. 1999;96:857-868.
15. Burgering BM, Kops GJ. Cell cycle and death control: long live Forkheads. Trends Biochem Sci. 2002;27:352-360.
16. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-κB: its role in health and disease. J Mol Med. 2004;82:434-448.
17. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med. 2005;111:183-190.
18. Arkan MC, Hevener AL, Greten FR, et al. IKK-β links inflammation to obesity-induced insulin resistance. Nat Med. 2005;111:191-198.
19. Cai D, Frantz DF, Tawa NE, et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell. 2004;119:285-298.
20. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285-296.
21. Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461-466.
22. Huber MA, Azoitei N, Baumann B, et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004;114:569-581.
23. Luo J-L, Maeda S, Hsu L-C, Yagita H, Karin M. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell. 2004;6:297-305.
24. Li Q, Withoff S, Verma IM. Inflammation-associated cancer:NF-kB is the lynchpin. Trends Immunol. 2005;26:318-325.
25. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature. 1995;376:167-170.
26. Tanaka M, Fuentes ME, Yamaguchi K, et al. Embryonic lethality, liver degeneration, and impaired NF-κB activation in IKK-β deficient mice. Immunity. 1999;10:421-429.
27. Doi TS, Marino MW, Takahashi T, et al. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci. 1999;96:2994-2999.
28. Rosenfeld ME, Prichard L, Shiojiri N, Fausto N. Prevention of hepatic apoptosis and embryonic lethality in RelA/TNFR-1 double knockout mice. Am J Pathol. 2000;156:997-1007.
29. Senftleben U, Li Z-W, Baud V, Karin M. Ikkβ is essential for protecting T cells from TNFα-induced apoptosis. Immunity. 2001;14:217-230.
30. Horowitz BH, Scott ML, Cherry SR, Bronson RT, Baltimore D. Failure of lymphopoiesis after adoptive transfer of NF-κB-deficient fetal liver cells. Immunity. 1997;6:765-772.
31. Grossmann M, Metcalf D, Merryfull J, Beg A, Baltimore D, Gerondakis S. The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci. 1999;96:11848-11853.
32. Maeda S, Chang L, Li ZW, et al. IKKβ is required for prevention of apoptosis mediated by cellbound but not circulating TNFα. Immunity. 2003;19:725-737.
33. Savinainen A, Kujawa J, Silva M, et al. IKK2 inhibition protects against bone and cartilage destruction in rat models of rheumatoid arthritis [abstract]. Inflamm Res. 2004;53:S225.
34. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell. 1996;84:853-862.
35. Lee FS, Hagler J, Chen ZJ, Maniatis T. Activation of the IκBα kinase complex by MEKK1, a kinase of the JNK pathway. Cell. 1997;88:213-222.
36. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-κB activity. J Immunol. 2002;168:1441-1446.
37. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest. 2001;107:7-11.
38. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002;2:920-932.
39. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647.
40. Siebenlist U, Brown K, Claudio E. Control of lymphoctye development by nuclear-factor κB. Nat Rev Immunol. 2005;5:435-445.
41. Kaisho T, Takeda K, Tsujimura T, et al. IκB kinase α is essential for mature B cell development and function. J Exp Med. 2001;193:417-426.
42. Senftleben U, Cao U, Xiao G, et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science. 2001;293:1495-1499.
43. Pasparakis M, Schmidt-Supprian M, Rajewsky K. IκB kinase signaling is essential for maintenance of mature B cells. J Exp Med. 2002;196:743-752.
44. Li ZW, Omori SA, Labuda T, Karin M, Rickert RC. IKKκ is required for peripheral B cell survival and proliferation. J Immunol. 2003;170:4630-4637.
45. Aggarwal BB. Signaling pathways of the TNF superfamily: a double edged sword. Nat Rev Immunol. 2003;3:745-756.
46. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol. 2001;2:1-10.
47. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647-656.
48. Opferman JT, Korsmeyer SJ. Apoptosis in the development of the immune system. Nat Immunol. 2003;4:410-415.
49. Peschon JJ, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol. 1998;160:943-952.
50. Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step towards immune competence. Trends Immunol. 2003;24:342-348.
51. Miagkov AV, Kovalenko DV, Brown CE, et al. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci U S A.1998;95:13859-13864.
52. Bondeson J, Foxwell B, Brennan F, Feldmann M. Defining therapeutic targets by using adenovirus: blocking NF-κB inhibits both inflammatory and destructive mechanism in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci U S A. 1999;96:5668-5673.
53. Campbell IK, Gerondakis S, O'Donnell K, Wicks IP. Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest. 2000;105:1799-1806.
54. Tak PP, Gerlag DM, Aupperle KR, et al. Inhibitor of nuclear factor κB kinase β is a key regulator of synovial inflammation. Arthritis Rheum. 2001;44:1897-1907.
55. Edwards JC, Szczepanski L, Szenchinski J, et al. Efficacy of B-cell-targeted therapy with Rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-2581.
56. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2:927-937.